Case Report

Rare Cause of Wide QRS Tachycardia

Nikolay Yu. Mironov, Natalia A. Mironova, Marina A. Saidova, Olga V. Stukalova, and Sergey P. Golitsyn

1Department of Clinical Electrophysiology, Russian Cardiology Research Center, Russia
2Department of Sonography, Russian Cardiology Research Center, Russia
3Department of Tomography, Russian Cardiology Research Center, Russia

Correspondence should be addressed to Nikolay Yu. Mironov; hukmup@gmail.com

Received 20 August 2015; Accepted 17 November 2015

1. Introduction

Myotonic dystrophy (MD) is a rare genetic progressive neuromuscular disease. The prevalence of MD in general population is 1:8000 [1]. MD affects skeletal muscle resulting in increased muscular tonus (myotonia) and progressive muscular weakness. Multiple organs are also involved. Disease is associated with significant morbidity and mortality. Respiratory failure and cardiovascular pathology were the most prevalent causes of death, accounting for about 40% and 30% of fatalities, respectively. Cardiac mortality occurs because of progressive left ventricular dysfunction, ischaemic heart disease, or pulmonary embolism or as a result of sudden death [2]. Commonly cardiac involvement develops later in the course of disease in patients with previously established diagnosis and prominent neuromuscular symptoms. Occasionally, cardiac involvement may be the first sign of MD [3]. We report a case of bundle branch reentrant ventricular tachycardia as primary manifestation of myotonic dystrophy and discuss associated diagnostic and treatment challenges.

2. Case Presentation

A 45-year-old male with no previous cardiac disease and unremarkable familial history was admitted due to recurrent hour-lasting episodes of chest pain that was caused by wide QRS tachycardia that required DC cardioversion.

Upon admission patient was oriented, in no acute distress, well developed, and well nourished (body mass index 30 kg/m^2). He denied smoking, alcohol abuse, and illicit drug use. Physical examination revealed hyperhidrosis. Patient’s axillar temperature was 36.4°C (97.5°F), blood pressure was 110/80 mmHg on both arms, pulse was 86 bpm with a regular rhythm, and respiratory rate was 18 breaths/min. Chest and abdomen investigation was unremarkable. Extremities were warm and well perfused, with normal range of motion and no edema. Slight binocular ptosis and moderate peripheral muscle weakness were noted. Patient had no severe cognitive defects.

Clinical blood, thyroid, and coagulologic profiles were normal. Biochemistry panel revealed hyperlipidemia (total cholesterol 6.5 mmol/L [253 mg/dL], LDL-cholesterol 3.8 mmol/L [148.3 mg/dL]), and modestly elevated creatine kinase 347 U/L. Troponin test was negative. HbA1c level was 6.1%. BNP level was less than 10 pg/mL.

ECG at rest displayed sinus rhythm (95 bpm), PQ (200 ms), QRS (120 ms), and single premature ventricular complexes (Figure 1). 24-hour ECG monitoring registered 524 single premature ventricular beats with no significant sustained arrhythmias and pauses. Echocardiography revealed...
asymmetric nonobstructive hypertrophy of ventricular septum (up to 16 mm in basal segment) with preserved LVEF, no wall motion abnormalities, and enlarged LA (4.4 cm; volume 90 mL).

Cardiac MRI demonstrated areas of subendocardial late gadolinium enhancement in septal, inferior, and lateral walls of LV, indicating focal fibrosis (Figure 2). Although subendocardial accumulation is typical for ischemic lesions, coronary angiography revealed intact arteries.

Electrophysiologic study showed delayed conduction in His-Purkinje system (HPS). HV interval duration was 74 ms (Figure 3(a)). Right ventricle pacing repeatedly induced bundle branch reentrant VT with a rate of 250 bpm and RBBB morphology with anterograde conduction over RBB and retrograde conduction over LBB (Figure 3(b)). All episodes of VT very successfully terminated by burst pacing. Considering structural heart disease and HPS involvement the decision was to refrain from radiofrequency ablation (RFA) and to implant 2-chamber ICD.

Brain MRI prior to implantation showed multiple vascular lesions in white matter and anterior temporal lobe hyperintensities on T2-weighted and FLAIR images (Figure 4).

Patient was discharged on Bisoprolol 7.5 mg OD and referred to neurological center for further investigation where diagnosis of myotonic dystrophy (MD) was confirmed by electromyography. Genetic test revealed multiple CTG repeats in DMPK gene.

A 10-month follow-up was remarkable for significant progression of neuromuscular symptoms. However there were no signs of heart disease progression on ECG and echocardiography. ICD telemetry showed 4 appropriate shocks delivered to one episode of fast VT and multiple long-lasting episodes of Afb with mean ventricular rate of 86 bpm that were asymptomatic and diagnosed only at ICD interrogation. Considering hypertrophic cardiomyopathy anticoagulant therapy by rivaroxaban 20 mg OD was initiated.

We desired to refrain from RFA procedure again. ICD was reprogrammed to more aggressive antitachycardial pacing by addition of 4 extra burst pacing packs of shorter cycle length. In subsequent 8-month follow-up there were 3 sustained fast VT detections. All of them were terminated by burst pacing and were asymptomatic.

### 3. Discussion

Myotonic dystrophy type (MD) is the most common muscular dystrophy in adults. There are 2 forms of disease: MD type 1 (caused by expansion of a CTG trinucleotide repeat in the 5’-untranslated region of the dystrophia myotonica protein kinase gene [DMPK gene]) and MD type 2 (caused by an expanded CCTG tetranucleotide repeat expansion located in intron 1 of the zinc finger protein 9 gene [ZNF9]). Exact proportions in prevalence of MD type 1 and MD type 2 are unknown [1].

Cardiac involvement is frequent in both forms of MD but commonly affects patients with prominent neuromuscular symptoms [3, 4]. Cardiac disease is characterized by progressive conduction system abnormalities, supraventricular and
ventricular arrhythmias, sudden death, and, less frequently, myocardial dysfunction (hypertrophic and, rarely, dilative cardiomyopathy) and ischaemic heart disease [5]. Conduction abnormalities that are of progressive course and potentially malignant may be found at any level of cardiac conduction system but commonly are located in HPS [4, 6]. In a study of 408 patients Groh et al. found that severe ECG abnormalities (rhythm other than sinus, PR interval of 240 ms or more, QRS duration of 120 ms or more, or second-degree or third-degree atrioventricular block) predict sudden death in type 1 MD [4]. ESC guidelines recommend pacemaker implantation if patient with MD develops any symptoms that may be caused by conduction system defect even if he has minor conduction abnormalities and does not meet classic pacemaker indications [7]. Tachyarrhythmias are also prevalent in MD patients. Most common arrhythmia is AFib. It is observed in up to 25% of patients in both sustained and nonsustained forms [4, 6, 8]. Since there are no data on risk of thromboembolic complications in that subset of patients, it is reasonable to use CHA2DS2-VASc score to define indications to anticoagulants. Malignant ventricular arrhythmias including monomorphic and polymorphic VT and spontaneous VF are also described. Delayed impulse conduction along HPS represents ideal substrate for bundle branch reentrant VT [9]. ICD is indicated in all patients with MD with sustained ventricular arrhythmias due to high risk of sudden death [4, 10]. RFA of RBB or LBB may be successfully applied in patients with bundle branch reentrant VT [1, 6].

Brain involvement is common, resulting in cognitive dysfunction, behavioral changes, apathy, and excessive daytime somnolence [1]. It should be noted that almost exclusively white matter lesions are found in MRI scans of patients with MD [11]. The origin of glious lesions in grey matter of both temporal lobes in our patient remained unknown.

In our case upon admission patient had only moderate neuromuscular symptoms but severe life-threatening ventricular arrhythmias that required ICD implantation. Furthermore, his familial history was unremarkable. Verification of uncommon cardiac lesions led to extensive diagnostic approach with suspicion of neuromuscular disease and subsequent referral to neurologic center, where the exact diagnosis of MD was made.

Taking into consideration small number of episodes of bundle branch reentrant VT, cardiac conduction system
defects, and increased risk of LV dysfunction progression on permanent pacing, we desired to refrain from RFA, which is frequently referred to as method of choice in management of bundle branch reentrant VT. Thorough optimization of ICD antitachycardic pacing parameters helped to terminate recurrent paroxysms. We did not initiate amiodarone therapy that based on data that antiarrhythmic drugs rarely prevent bundle branch reentrant VT [9] and because of the risks of neurotoxicity that may be higher in patients with pre-existent neurological disorders. We continued a close follow-up and if patient will have multiple episodes of bundle branch reentrant VT, either antiarrhythmic drug therapy might be initiated or he might be readmitted for RFA procedure. It should be noted that there was no significant cardiac disease progression in 18-month follow-up which could be frequently observed in patients with LBBB after bundle branch reentrant VT ablation [12].

Despite hyperlipidemia and high cardiometabolic risk, decision to refrain from statin prescription was made, powered by transient creatine kinase elevations and observations that patients with muscular metabolic abnormalities are more prone to statin-induced myopathy [13].

In the case described patient developed AFib significantly later than VT in the course of the disease. From the onset of
the first paroxysm there is clear trend in AFib progression to permanent form. Although AFib was generally asymptomatic, it was clinically significant and required anticoagulation taking into consideration the presence of significant LV septal hypertrophy and high risk of cardioembolic events in patients with hypertrophic cardiomyopathy and AFib [14, 15]. Noteworthy, in this case CHADS\(_2\) and CHA\(_2\)DS\(_2\)-VASc scales were useless as the patient’s score was zero.

4. Conclusion

Our case illustrates that cardiac arrhythmias in patients with MD may be more severe than neuromuscular symptoms, and their management could be challenging. Stepwise approach should be applied. Thorough consideration of pros and cons of any therapeutic modality is mandatory because these patients may not benefit from routine treatment strategies.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

The authors would like to thank Drs. Sergey Sokolov, Nikolay Shlevkov, and Yury Mareev for their contribution to diagnostic work-up and follow-up of patient.

References

[1] B. T. Darras and D. A. Chad, "Myotonic dystrophy: etiology, clinical features, and diagnosis," May 2015, http://www.uptodate.com/contents/myotonic-dystrophy-etiologyclinical-features-and-diagnosis.

[2] J. Mathieu, P. Allard, L. Potvin, C. Prévost, and P. Begin, "A 10-year study of mortality in a cohort of patients with myotonic dystrophy," Neurology, vol. 52, no. 8, pp. 1658–1662, 1999.

[3] V. A. Sansone, E. Brigonzi, B. Schoser et al., “The frequency and severity of cardiac involvement in myotonic dystrophy type 2 (DM2): long-term outcomes,” International Journal of Cardiology, vol. 168, no. 2, pp. 1147–1153, 2013.

[4] W. J. Groh, M. R. Groh, C. Saha et al, “Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1,” The New England Journal of Medicine, vol. 358, no. 25, pp. 2688–2697, 2008.

[5] M. F. Phillips and P. S. Harper, "Cardiac disease in myotonic dystrophy," Cardiovascular Research, vol. 33, no. 1, pp. 13–22, 1997.

[6] G. Pelargonio, A. Dello Russo, T. Sanna, G. De Martino, and F. Bellocchi, “Myotonic dystrophy and the heart,” Heart, vol. 88, no. 6, pp. 665–670, 2002.

[7] M. Brignole, A. Auricchio, G. Baron-Esqivias et al., “2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy,” The Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA),” Europace, vol. 15, no. 8, pp. 1070–1118, 2013.

[8] B. Udd and R. Krahe, “The myotonic dystrophies: molecular, clinical, and therapeutic challenges," The Lancet Neurology, vol. 11, no. 10, pp. 891–905, 2012.

[9] J. L. Merino, J. R. Carmona, I. Fernández-Lozano, R. Peinado, N. Basterra, and J. A. Sobrino, “Mechanisms of sustained ventricular tachycardia in myotonic dystrophy: implications for catheter ablation,” Circulation, vol. 98, no. 6, pp. 541–546, 1998.

[10] D. Bhakta, C. Shen, J. Kron, A. E. Epstein, R. M. Pascuzzi, and W. J. Groh, "Pacemaker and implantable cardioverter-defibrillator use in a US myotonic dystrophy type 1 population," Journal of Cardiovascular Electrophysiology, vol. 22, no. 12, pp. 1369–1375, 2011.

[11] M.-L. Caillet-Boudin, F.-J. Fernandez-Gomez, H. Tran, C.-M. Dhuenens, L. Buee, and N. Sergeant, “Brain pathology in myotonic dystrophy: when tauopathy meets spongiosis and RNAopathy,” Frontiers in Molecular Neuroscience, vol. 6, article 57, 2014.
reentry,” *Clinical Research in Cardiology*, vol. 102, no. 2, pp. 145–153, 2013.

[13] G. D. Vladutiu, Z. Simmons, P. J. Isackson et al., “Genetic risk factors associated with lipid-lowering drug-induced myopathies,” *Muscle and Nerve*, vol. 34, no. 2, pp. 153–162, 2006.

[14] B. J. Gersh, B. J. Maron, R. O. Bonow et al., “2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy,” *Circulation*, vol. 124, no. 24, pp. e783–e831, 2011.

[15] I. Olivotto, F. Cecchi, S. A. Casey, A. Dolara, J. H. Traverse, and B. J. Maron, “Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy,” *Circulation*, vol. 104, no. 21, pp. 2517–2524, 2001.